RE: Orphan drug status2 Mar 2023 10:47
Thanks Tyke,
Some interesting points in that article..
"Bioentrepreneurs and investors that keep their equity stake in a company with an orphan-designated product from Phase 1 until FDA approval can expect to increase their initial capital by 7.2x (95%CI 5.6–9.0) which translates to annual returns of 46% (95%CI 37–56) after adjusting for drug failures (Table 2)."
If I was TB I think I'd be pimping for offers and be ready to take the money and run.